Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab Safety Study in Advanced NSCLC (CheckMate 955)
NCT03048136Phase 3Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2018
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Planned start Mar 2018; status: withdrawn.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03048136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03048136.